Drug intelligence / Profile preview

ST002

Development stage: Unknown
Lead developer: SteroTherapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Injection

Overview

ST002 is a gene therapy product designed for the treatment of Neurofibromatosis Type 2 (NF2) mutation-related solid tumors. It functions by reinserting the normal NF2 gene into genetically deficient tumor cells. This reinsertion leads to the expression of the Merlin protein, which subsequently regulates gene transcription, controls the tumor microenvironment, and inhibits tumor growth and invasion, thereby achieving therapeutic effects.

Targets

NF2 (Neurofibromin-2 (Merlin))

Beyond the preview

Go deeper on ST002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST002.

Explore the full profile